Amicus plans Phase III trial for novel Fabry disease drug
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics has finalised the programme for a pivotal Phase III trial of Amigal (migalastat hydrochloride) in Fabry disease. The company plans to begin enrolling and dosing subjects with its lead product in the second half of this year.